Pfizer Plans To Restart Tanezumab Trials In 2014
This article was originally published in The Pink Sheet Daily
While questions about the company’s internal reorganization dominated its second-quarter earnings call, Pfizer management also provided some clinical and pipeline updates. Pfizer said the partial clinical hold on its anti-nerve growth factor tanezumab has been lifted and it is preparing to begin Phase III clinical trials in 2014.
You may also be interested in...
With galcanezumab for cluster headaches and migraine and tanezumab for osteoarthritis, lower back pain and cancer pain, Lilly soon could have an up-and-running pain franchise bolstering its long-term, internal R&D strategy.
Pfizer and Lilly plan to resume Phase III testing of their nerve growth factor inhibitor after FDA lifted a partial hold on tanezumab. But J&J is also poised to run new Phase III studies with fulranumab.
Glyxambi is the latest in a series of new diabetes drugs for Eli Lilly, following on the heels of Jardiance and Trulicity. The company highlighted new drugs and its pipeline during its year-end financial call.